Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2011 2
2012 4
2013 5
2014 9
2015 3
2016 7
2017 10
2018 7
2019 12
2020 11
2021 4
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine-associated acute interstitial pneumonitis.
Kuroda J, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Chinen Y, Maegawa S, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Kuroda J, et al. Among authors: chinen y. Intern Med. 2014;53(11):1165-9. doi: 10.2169/internalmedicine.53.1971. Epub 2014 Jun 1. Intern Med. 2014. PMID: 24881742 Free article.
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.
Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Muramatsu A, et al. Among authors: chinen y. Leuk Lymphoma. 2022 Jul;63(7):1678-1685. doi: 10.1080/10428194.2022.2038373. Epub 2022 Feb 11. Leuk Lymphoma. 2022. PMID: 35147475
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Nishiyama D, et al. Among authors: chinen y. Int J Hematol. 2021 Mar;113(3):381-394. doi: 10.1007/s12185-020-03027-0. Epub 2020 Oct 23. Int J Hematol. 2021. PMID: 33095415
[Chromosomes and genes].
Taniwaki M, Chinen Y. Taniwaki M, et al. Among authors: chinen y. Nihon Rinsho. 2012 Apr;70 Suppl 2:62-8. Nihon Rinsho. 2012. PMID: 23133929 Japanese. No abstract available.
Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma.
Matsumoto Y, Tsukamoto T, Chinen Y, Shimura Y, Sasaki N, Nagoshi H, Sato R, Adachi H, Nakano M, Horiike S, Kuroda J, Taki T, Tashiro K, Taniwaki M. Matsumoto Y, et al. Among authors: chinen y. J Clin Exp Hematop. 2021 Jun 5;61(2):71-77. doi: 10.3960/jslrt.20033. Epub 2021 Apr 20. J Clin Exp Hematop. 2021. PMID: 33883344 Free PMC article.
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida SI, Shimazaki C, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Shimura Y, Horiike S, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: chinen y. Cancer Rep (Hoboken). 2022 Feb;5(2):e1476. doi: 10.1002/cnr2.1476. Epub 2021 Jun 14. Cancer Rep (Hoboken). 2022. PMID: 34124862 Free PMC article.
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.
Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J. Sakiyama E, et al. Among authors: chinen y. Infect Drug Resist. 2020 Apr 8;13:1017-1021. doi: 10.2147/IDR.S249030. eCollection 2020. Infect Drug Resist. 2020. PMID: 32308443 Free PMC article.
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: chinen y. Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24. Int J Hematol. 2022. PMID: 35072907
67 results